The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.
J Exp Med
; 196(3): 359-68, 2002 Aug 05.
Article
en En
| MEDLINE
| ID: mdl-12163564
ABSTRACT
Allogeneic stem cell transplantation (SCT) can induce curative graft-versus-tumor reactions in patients with hematological malignancies and solid tumors. The graft-versus-tumor reaction after human histocompatibility leukocyte antigen (HLA)-identical SCT is mediated by alloimmune donor T cells specific for polymorphic minor histocompatibility antigens (mHags). Among these, the mHag HA-1 was found to be restricted to the hematopoietic system. Here, we report on the HA-1 ribonucleic acid expression by microdissected carcinoma tissues and by single disseminated tumor cells isolated from patients with various epithelial tumors. The HA-1 peptide is molecularly defined, as it forms an immunogenic peptide ligand with HLA-A2 on the cell membrane of carcinoma cell lines. HA-1-specific cytotoxic T cells lyse epithelial tumor cell lines in vitro, whereas normal epithelial cells are not recognized. Thus, HA-1-specific immunotherapy combined with HLA-identical allogeneic SCT may now be feasible for patients with HA-1(+) carcinomas.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Oligopéptidos
/
Antígenos de Histocompatibilidad Menor
/
Neoplasias Glandulares y Epiteliales
Límite:
Humans
Idioma:
En
Revista:
J Exp Med
Año:
2002
Tipo del documento:
Article
País de afiliación:
Alemania